Download Free Synthetic Cathinones Bath Salts Book in PDF and EPUB Free Download. You can read online Synthetic Cathinones Bath Salts and write the review.

The National Drug Intelligence Center (NDIC) assesses with high confidence that the distribution and abuse of synthetic cathinones will increase in the United States in the near term, posing yet another challenge to U.S. law enforcement officials. Poison control centers and medical professionals around the country are increasingly reporting patients suffering adverse physical effects associated with abuse of these drugs, further compounding the problem. Available data and law enforcement reporting suggest increasing levels of synthetic cathinone availability and abuse, but such information is limited and precise levels are unknown. U.S. Customs and Border Protection (CBP) currently tracks seizures of synthetic cathinones at U.S. ports of entry (POEs), but many synthetic cathinone products are disguised or mislabeled to impede detection. Because common field test kits, drug-detecting canines, and routine urine drug screens do not detect synthetic cathinones, law enforcement officials are challenged in interdicting such drugs and prosecuting their manufacturers and distributors. Synthetic cathinones, typically marketed as "bath salts" and "plant food," are sold legally under various names (Ivory Wave, Blizzard, etc.) in most areas of the United States. The products are generally sold in retail establishments such as adult stores, independently owned convenience stores, gas stations, head shops, and skateboard shops. The products, as well as their raw chemical components, are also sold on many Internet sites, including popular Internet auction sites. Additionally, synthetic cathinones have been sold by independent dealers as ecstasya-in powdered form, in single-component tablets and capsules, and in tablets and capsules containing cathinones combined with MDMA (3,4-methylenedioxymethamphetamine) or other illicit controlled substances. Abusers typically ingest, inhale, inject, smoke, or snort (insufflate) the drugs to experience stimulant effects similar to those induced by amphetamine. Manufacturers and distributors of synthetic cathinone products evade U.S. Drug Enforcement Administration (DEA) regulation and enforcement because synthetic cathinones are not scheduled under the Federal Controlled Substances Act (CSA). However, possession and distribution of the synthetic cathinones may be prosecuted, albeit with greater difficulty, under the Federal Controlled Substance Analogue Enforcement Act of 1986 (as amended)b of the CSA. The availability and suitability of a prosecution under the analogue statute depends on the particular compound being trafficked and the facts of the case. Further, distributors deceptively market synthetic cathinone products as "not for human consumption" to evade U.S. Food and Drug Administration (FDA) scrutiny. Cathinone products that are introduced into interstate commerce and promoted as alternatives to illicit street drugs may be prosecutable under the Federal Food, Drug, and Cosmetic Act as unapproved new drugs and misbranded drugs. (See the offenses at 21 U.S.C. 331(a), (d) and penalties at 21 U.S.C. 333.)1 Additionally, members of the Congress have introduced legislation to nationally ban the sale of certain synthetic cathinones, c and, as of April 2011, all 50 states and the District of Columbia have introduced or announced plans to introduce legislation banning or restricting the distribution and possession of certain synthetic cathinones and cathinone derivatives. As synthetic cathinones become more regulated, abusers will likely use the Internet with greater frequency to purchase cathinone products, the raw chemicals used in their production, and products that contain cathinones not specifically prohibited by enacted legislation.
Synthetic cathinones are central nervous system stimulants. Typically marketed as "bath salts" and "plant food," synthetic cathinones sold legally under various names (Ivory Wave, Blizzard, etc.) in most areas of the United States. The National Drug Intelligence Center (NDIC) assesses with high confidence that the distribution and abuse of synthetic cathinones will increase in the United States in the near term, posing yet another challenge to U.S. law enforcement officials.
Over the last decade, and particularly during the recent five years, a rapidly increasing number of novel psychoactive substance (NPSs), often marketed as “designer drugs”, “legal highs”, “herbal highs”, “research or intermediate chemicals” and “laboratory reagents”, has appeared on the drug market in an effort to bypass controlled substance legislation. NPSs encompass a wide range of different compounds and drug classes but had been dominated by synthetic cannabinomimetics and psychostimulatory synthetic cathinones, so-called β-keto amphetamines. Compounds from the later class were first detected in Europe in 2004, and since then 103 new cathinones have been identified and reported to the European Monitoring Centre for Drugs and Drug Addiction, with 57 during the last two years. Synthetic cathinones – novel addictive and stimulatory psychoactive substances is the first publication of this kind that provides readers with background on chemical structures, detection, prevalence and motivation of use of the very popular group of NPSs. This book also presents comprehensive overview of the mechanisms of action, pharmacological activity, and main metabolic pathways of synthetic cathinones, followed by a detailed discussion of the acute and chronic toxicity associated with the use of these substances. Written by international experts in the field, this multi-authored book is a valuable reference not only for scientists, clinicians and academics, but also for readers representing different professional background who are involved in educational-prophylactic activities directed to harm reduction of psychoactive compounds.
Although they are labeled "not for human consumption," bath salts and other synthetic drugs are the latest craze for getting high--and they have already proved to be dangerous and unpredictable. Through objective overviews, primary sources, and full color illustrations this title examines How Serious a Problem Is Synthetic Drug Abuse? What Are the Dangers of Synthetic Drugs? How Should Synthetic Drugs Be Regulated? and How Can Synthetic Drug Abuse Be Prevented?
The National Drug Intelligence Center (NDIC) has prepared these important dangerous drug alerts about unique and serious threats: Synthetic Cathinones (Bath Salts), Mephedrone, Synthetic Cannabinoids, Purple Drank, Synthetic Hallucinogen 2C-E, Oxymorphone Abuse, Opium Tea, Salvia Divinorum. Synthetic cathinones, typically marketed as "bath salts" and "plant food," are sold legally under various names (Ivory Wave, Blizzard, etc.) in most areas of the United States. The products are generally sold in retail establishments such as adult stores, independently owned convenience stores, gas stations, head shops, and skateboard shops. The products, as well as their raw chemical components, are also sold on many Internet sites, including popular Internet auction sites. Additionally, synthetic cathinones have been sold by independent dealers as ecstasy a-in powdered form, in single-component tablets and capsules, and in tablets and capsules containing cathinones combined with MDMA (3,4-methylenedioxymethamphetamine) or other illicit controlled substances. Abusers typically ingest, inhale, inject, smoke, or snort (insufflate) the drugs to experience stimulant effects similar to those induced by amphetamine. Manufacturers and distributors of synthetic cathinone products evade U.S. Drug Enforcement Administration (DEA) regulation and enforcement because synthetic cathinones are not scheduled under the Federal Controlled Substances Act (CSA). However, possession and distribution of the synthetic cathinones may be prosecuted, albeit with greater difficulty, under the Federal Controlled Substance Analogue Enforcement Act of 1986 (as amended)b of the CSA. The availability and suitability of a prosecution under the analogue statute depends on the particular compound being trafficked and the facts of the case. Further, distributors deceptively market synthetic cathinone products as "not for human consumption" to evade U.S. Food and Drug Administration (FDA) scrutiny. Cathinone products that are introduced into interstate commerce and promoted as alternatives to illicit street drugs may be prosecutable under the Federal Food, Drug, and Cosmetic Act as unapproved new drugs and misbranded drugs. (See the offenses at 21 U.S.C. 331(a), (d) and penalties at 21 U.S.C. 333.)1 Additionally, members of the Congress have introduced legislation to nationally ban the sale of certain synthetic cathinones, c and, as of April 2011, all 50 states and the District of Columbia have introduced or announced plans to introduce legislation banning or restricting the distribution and possession of certain synthetic cathinones and cathinone derivatives. As synthetic cathinones become more regulated, abusers will likely use the Internet with greater frequency to purchase cathinone products, the raw chemicals used in their production, and products that contain cathinones not specifically prohibited by enacted legislation. The illicit trafficking and abuse of drugs present a challenging, dynamic threat to the United States. Overall demand is rising, largely supplied by illicit drugs smuggled to U.S. markets by major transnational criminal organizations (TCOs). Changing conditions continue to alter patterns in drug production, trafficking, and abuse. Traffickers are responding to government counterdrug efforts by modifying their interrelationships, altering drug production levels, and adjusting their trafficking routes and methods. Major Mexican-based TCOs continue to solidify their dominance over the wholesale illicit drug trade as they control the movement of most of the foreign-produced drug supply across the U.S. Southwest Border.
Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. Serves as a ready resource of information for alcohol and drug testing Ideal resource for making decisions related to the monitoring and interpretation of results Includes concise content for clinical laboratory scientists, toxicologists and clinicians
The Psychopharmacology of Hallucinogens focuses on the properties, compositions, functions, transformations, and reactions of hallucinogens. The selection first offers information on the biosynthesis and action of hallucinogens in mammals; role of biogenic amines in the actions of monomethoxy-amphetamines; and molecular mechanism of action of hallucinogens. The book then takes a look at the molecular determinants for interaction with the LSD receptor, including biological studies, molecular reactivity, and summation of the molecular polarization complexes. The text examines the progress on the development of a receptor model for hallucinogenic amphetamines; characterization of psychotomimetics; physical identification of hallucinogenic compounds; and aspects of the pharmacology of phencyclidine. The book also underscores the effects of LSD, mescaline, and DMT, including effects on humans, proposed model, and effects of monoamine manipulations. The text also presents analysis of hallucinogens by Pavlovian conditioning, behavioral measures of hallucinogenic behavior, and drug model of hallucinosis. The selection is a dependable reference for readers interested in the study of hallucinogens.
Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials. Features accessible language for healthcare and safety professionals who are not experts in laboratory procedures Provides examples from clinical and everyday situations Explains how to interpret laboratory results and the latest genetic factors regarding drug and alcohol abuse
Designer drugs, or new psychoactive substances (NPS), are synthetic chemicals that mimic the effects of classic drugs of abuse. There has been an alarming worldwide increase in the abuse of NPS in recent years. NPS are cheap, easy to obtain, and often legally available. In this volume, leading experts summarize the latest studies regarding the molecular mechanisms of action, behavioral effects, and adverse consequences of popular NPS. Specific chapters clarify the differences between various types of NPS, namely: stimulants, cannabinoids and hallucinogens. Thus, this volume broadens our understanding of NPS and provides insight into the rapidly evolving “new drug” phenomenon.
Synthetic cathinones are stimulant drugs of abuse that act at monoamine transporters e.g. the dopamine transporter (DAT) as releasing agents or as reuptake inhibitors. More than>150 new synthetic cathinones have emerged on the clandestine market and have attracted considerable attention from the medical and law enforcement communities. threo-Methylphenidate (tMP) is an FDA approved drug for the treatment of ADHD and narcolepsy, which also acts as a DAT reuptake inhibitor and is widely abused. tMP and synthetic cathinones share some structural similarities and extensive structure-activity relationship (SAR) studies on tMP have been conducted. However, much less is known about the SAR of synthetic cathinones, and the available MP literature might assist in understanding it. The main focus of this research was to compare SAR between methylphenidate-cathinone hybrids and available methylphenidate SAR in order to identify some guiding principles that might allowus to predict their abuse potential and to identify which cathinones should betargeted for more extensive evaluation. In the present study, we evaluated eight 2-benzoylpiperidine analogs and a descarbonyl analog to determine if tMP SAR can be applied to cathinone SAR. We conducted molecular modeling and docking studies and predicted the order of potency to be tMP> 2-benzoylpiperidine> 2-benzylpiperidine based on the number of hydrogen bonds. The synthesized analogs were evaluated in a competition assay using live-cell imaging against APP+ in HEK293 cells stably expressing hDAT. All compounds were found to be DAT reuptake inhibitors and, as the modeling studies predicted, the order of potency in our functional studies was also found to be tMP> 2-benzoylpiperidine> 2- benzylpiperidine. A significant correlation was obtained between the potency of the benzoylpiperidines and tMP binding data (r = 0.91) suggesting that the SAR of tMP analogs might be applicable to the synthetic cathinones as DAT reuptake inhibitors.